Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ficerafusp alfa - Bicara Therapeutics

Next Previous
Drug Profile

Ficerafusp alfa - Bicara Therapeutics

Alternative Names: BCA-101; EGFR/TGFβ fusion monoclonal antibody - Bicara Therapeutics

Latest Information Update: 03 Dec 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bicara Therapeutics
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies; Recombinant fusion proteins
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Squamous cell cancer
  • Phase I Solid tumours

Most Recent Events

  • 01 Dec 2025 Updated efficacy data from a phase-I/Ib trial in Solid tumours released by Bicara Therapeutics
  • 19 Nov 2025 Ficerafusp alfa is still in phase-I development in Solid-tumours (Combination therapy, Late-stage disease, Second-line therapy or greater) in Australia (IV, Infusion)
  • 19 Nov 2025 Ficerafusp alfa is still in phase-I development in Solid-tumours (Combination therapy, Late-stage disease, Second-line therapy or greater) in Canada (IV, Infusion)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top